Mesoblast Ltd (MESO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mesoblast Ltd (MESO) has a cash flow conversion efficiency ratio of -0.016x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.26 Million) by net assets ($568.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Mesoblast Ltd for the company's overall valuation and market capitalisation.
Mesoblast Ltd - Cash Flow Conversion Efficiency Trend (2005–2026)
This chart illustrates how Mesoblast Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mesoblast Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mesoblast Ltd ranked by their cash flow conversion efficiency. Explore Mesoblast Ltd (MESO) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ruentex Industries Ltd
TW:2915
|
0.003x |
|
eToro Group Ltd.
NASDAQ:ETOR
|
0.028x |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
0.075x |
|
Hoist Finance AB
ST:HOFI
|
0.067x |
|
Pitney Bowes Inc
NYSE:PBI
|
-0.291x |
|
Beijing Jetsen Tech Co
SHE:300182
|
0.028x |
|
Ichor Holdings Ltd
NASDAQ:ICHR
|
-0.018x |
|
TBO Tek Ltd
NSE:TBOTEK
|
0.021x |
Annual Cash Flow Conversion Efficiency for Mesoblast Ltd (2005–2026)
The table below shows the annual cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2026. View MESO share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $568.40 Million | $-43.83 Million | -0.077x | +7.78% |
| 2025-06-30 | $597.44 Million | $-49.95 Million | -0.084x | +17.12% |
| 2024-06-30 | $480.36 Million | $-48.46 Million | -0.101x | +19.98% |
| 2023-06-30 | $501.84 Million | $-63.27 Million | -0.126x | +4.74% |
| 2022-06-30 | $497.04 Million | $-65.78 Million | -0.132x | +27.87% |
| 2021-06-30 | $581.40 Million | $-106.68 Million | -0.183x | -78.83% |
| 2020-06-30 | $549.33 Million | $-56.37 Million | -0.103x | +14.59% |
| 2019-06-30 | $481.05 Million | $-57.79 Million | -0.120x | +12.56% |
| 2018-06-30 | $546.01 Million | $-75.01 Million | -0.137x | +25.64% |
| 2017-06-30 | $516.77 Million | $-95.47 Million | -0.185x | -10.89% |
| 2016-06-30 | $528.16 Million | $-88.00 Million | -0.167x | +16.58% |
| 2015-06-30 | $609.36 Million | $-121.71 Million | -0.200x | -39.49% |
| 2014-06-30 | $571.72 Million | $-81.86 Million | -0.143x | -66.87% |
| 2013-06-30 | $630.27 Million | $-54.08 Million | -0.086x | +43.03% |
| 2012-06-30 | $478.85 Million | $-72.12 Million | -0.151x | -171.78% |
| 2011-06-30 | $515.84 Million | $108.23 Million | 0.210x | +182.38% |
| 2010-06-30 | $37.92 Million | $-9.66 Million | -0.255x | +28.89% |
| 2009-06-30 | $25.79 Million | $-9.24 Million | -0.358x | -51.39% |
| 2008-06-30 | $26.22 Million | $-6.20 Million | -0.237x | +46.61% |
| 2007-06-30 | $20.54 Million | $-9.10 Million | -0.443x | -66.55% |
| 2006-06-30 | $11.97 Million | $-3.18 Million | -0.266x | -747.50% |
| 2005-06-30 | $19.26 Million | $-604.81K | -0.031x | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid … Read more